The State of Clinical Development, a Series of Explorations Drug Development Innovates So Slowly

The State of Clinical Development, a Series of Explorations Drug Development Innovates So Slowly

Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite.

By early 2011, both Merck and Pfizer faced patent expirations resulting in significantly lower sales forecasts. In reaction, Pfizer cut his spending on research and development by a third, while it bought back shares worth five billion dollars. Nearly simultaneously Merck, for its part, decided to uphold its R&D spending, claiming it needed new products to revive its business.

In the direct reaction, Merck's stock price dropped 2.7 percent while Pfizer's stock price went up 5.2 percent.  

While this is a partial image, it illustrates some of the fundamental problems in the development of medications well. While long-term investments are paying off less and less, the pressure on long-term sales remains relentless. Due to this, we see mergers and the big companies buying up molecules from academics or start-ups once the highest risks are perceived to be mitigated. It is often referred to as pharma's broken business model, but considering the profits that are still made, it is more accurate to think of it as healthcare's broken business mode...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee